Dana-Farber Identifies CDK8 as Promising Target for Childhood Cancer
Boston, Massachusetts, USA | July 16, 2026 Dana-Farber Cancer Institute researchers have identified CDK8 as a promising therapeutic target...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
Boston, Massachusetts, USA | July 16, 2026 Dana-Farber Cancer Institute researchers have identified CDK8 as a promising therapeutic target...
BASEL, Switzerland, July 6, 2026 Novartis has announced a landmark agreement to acquire Myricx Bio, a UK-based biotechnology company...
CARLSBAD, California, July 2, 2026 Arima Genomics, Inc., a cancer diagnostics company advancing precision oncology through Hi-C sequencing technology,...
